DOCSLIB.ORG

Clinical Curriculum: Gynecologic Oncology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Curriculum: Gynecologic Oncology Reviewed July 2014 Clinical Curriculum: Gynecologic Oncology Goal: The primary goal of the gynecologic oncology rotation at the University of Alabama at Birmingham is to train residents to have a general understanding of the evaluation and treatment of women with suspected gynecologic malignancies. At the completion of four years of training, our residents will be capable of appropriate workup and referral of patients with gynecologic malignancies. Organization: Four residents are assigned to the UAB inpatient rotation (Green: PGY2 & 3; Gold: PGY1 & 4). One intern will be assigned to the outpatient clinic rotation. Junior residents (PGY1, 2) will also attend the Colposcopy Clinic on Friday mornings. Supervision: Residents are directly supervised by faculty members at all times. Gynecologic oncology faculty are in attendance in the operating rooms during the critical portion of all procedures. All admitted inpatients are seen by a faculty daily. By the end of the rotation, 1st and 2nd year residents should be able to perform: Workup and management of patients with suspected gynecologic malignancies Minor gynecologic procedures such as D&C, cold knife cone, and CO2 laser ablations Basic laparoscopy Routine open hysterectomy and salpingo-oophorectomy By the end of the rotation, 3rd and 4th year residents should be able to perform: Critical care of postoperative patients Robotic hysterectomy and salpingo-oophorectomy Complicated abdominal and pelvic surgery such as endometriosis and adhesions Reviewed July 2014 By the end of the rotation, residents should understand or perform the following procedures: Procedure Understand Perform Colectomy (partial or total) 1,2,3,4 Colostomy 1,2,3,4 Fistula repair 1,2,3,4 Hysterectomy: Extrafascial (with or without bilateral salpingo-oophorectomy) 1,2,3,4 Radical (with or without bilateral salpingo-oophorectomy) 1,2,3,4 Lumpectomy of breast 1,2,3,4 Lymph node biopsy/dissection: Axillary 1,2,3,4 Inguinal 1,2,3,4 Para-aortic 1,2,3,4 Pelvic 1,2,3,4 Sentinel 1,2,3,4 Mastectomy Radical 1,2,3,4 Simple 1,2,3,4 Paracentesis 1,2,3,4 Pelvic exenteration with or without reconstruction 1,2,3,4 IP port placement 1,2,3,4 Radiation therapy Brachytherapy 1,2,3,4 External beam 1,2,3,4 Interstitial 1,2,3,4 Resection of large and small bowel 1,2,3,4 Staging laparotomy Biopsy of pelvic lymph nodes 1,2,3,4 Biopsy of peritoneal implants and cytologic washings of the peritoneal cavity 3,4 Exploration of abdomen 3,4 Infracolic omentectomy 3,4 Suction evacuation of molar pregnancy 1,2,3,4 Transverse rectus abdominis myocutaneous flap 1,2,3,4 Vaginal reconstruction Gracilis flap 1,2,3,4 Martius flap 1,2,3,4 Reviewed July 2014 Skin graft 1,2,3,4 Venous access device placement 1,2,3,4 Vulvectomy 3,4 Gynecologic Oncology Objectives Basic science/mechanisms of disease PGY Genetics PC MK PBL ICS P SBP Level Describe the clinical relevance of oncogenes and tumor suppressor genes. 1,2,3,4 x Describe the inheritance patterns for malignancies of the pelvic organs and breast. 1,2,3,4 x Describe the current indications for screening for BRCA1, BRCA2, and hereditary 1,2,3,4 x nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome. Describe the cell replication cycle and identify the phases of the cycle most sensitive to 1,2,3,4 x radiation therapy and chemotherapy. Physiology Describe the ability of vital organ systems to tolerate cancer therapy and define the 1,2,3,4 x concept of therapeutic index. Describe the changes in cell and organ physiology that result from injury due to 1,2,3,4 x radiation therapy and chemotherapy. Embryology and developmental biology Describe the embryology of gonadal migration and its role in the pathogenesis of 1,2,3,4 x epithelial and germ cell neoplasms. Describe the embryologic origins of cell types found in benign and malignant germ cell 1,2,3,4 x tumors. Anatomy Describe the anatomy of the anterior and posterior abdominal wall. 1,2,3,4 x Describe the anatomy of the pelvic floor retroperitoneal and para-aortic spaces. 3,4 x Describe the gross and histologic anatomy of the external genitalia, pelvic organs, and 1,2,3,4 x the breast. Describe the vascular, lymphatic, and nerve supply to the breast, external genitalia, 1,2,3,4 x and each of the pelvic organs. Describe the anatomic relationship between the reproductive organs and the 3,4 x nongynecologic abdominal and pelvic viscera (ie, bladder, ureters, and bowel). Describe the likely changes in the anatomic relationships of the pelvic and abdominal viscera created by surgical or radiation treatment for a malignancy of the pelvic 3,4 x organs. Pharmacology Reviewed July 2014 List the major chemotherapeutic agents used for treatment of malignancies of the 2,3,4 x reproductive organs and breast. Describe the principal adverse effects of these major chemotherapeutic agents. 2,3,4 x List supportive care methods/medications that can be used to ameliorate the following treatment complications: a. Marrow suppression b. Nausea and vomiting 2,3,4 x c. Hemorrhagic cystitis d. Peripheral neuropathy e. Renal toxicity f. Cardiac toxicity Pathology and neoplasia Describe the role of viruses in the pathogenesis of gynecologic tumors. 1,2,3,4 x Describe the influence of immunosuppression on the risk of acquiring a type of gynecologic cancer. 1,2,3,4 x Describe the effect of cancer and its therapies on the immune system. 1,2,3,4 x List the principal consequences of immunosuppression in the cancer patient (eg, increased susceptibility to infection and poor wound healing). 1,2,3,4 x Carcinoma of the breast PGY Epidemiology and risk assessment of breast cancer PC MK PBL ICS P SBP Level Evaluate a patient’s personal or family history of breast cancer, including the risk 1,2,3,4 x x associated with BRCA1 or BRCA2. Evaluate other epidemiologic factors to assess a woman’s risk of developing breast cancer, such as the following: a. Patient age b. Parity 1,2,3,4 x x c. Ethnicity d. Lactation e. Hormone replacement f. Alcohol consumption Counsel patients regarding breast cancer prevention strategies. 1,2,3,4 x x Counsel patients regarding the use of screening methods, such as mammography. 1,2,3,4 x x Refer patients appropriately for genetic counseling and testing. 1,2,3,4 x x Reviewed July 2014 Diagnosis of invasive carcinoma of the breast Obtain a focused history and perform a physical examination in women with signs or 1,2,3,4 x x symptoms of breast cancer. Order and explain to the patient appropriate diagnostic tests for evaluating a 1,2,3,4 x x suspicious breast lesion. Describe the indications for and interpret the results of needle aspiration of a breast 1,2,3,4 x x cyst and fine needle biopsy of a solid lesion for the patient. Describe the indications for and interpret for the patient the results of other diagnostic studies, such as the following: a. Mammography b. Ultrasonography 1,2,3,4 x x c. Magnetic resonance imaging d. Core-needle biopsy e. Excisional biopsy Management of invasive breast cancer Describe the staging of breast cancer and the prognostic significance of histologic type, regional lymph node metastasis, distant metastasis, and hormone receptor 1,2,3,4 x status. Describe the indications for lumpectomy compared with mastectomy. 1,2,3,4 x Describe the indications for adjuvant therapy with hormonal treatment, chemotherapy, 1,2,3,4 x or radiation therapy. Describe the effect of pregnancy on the treatment and prognosis of breast cancer. 1,2,3,4 x Breast cancer survivorship Describe the psychosocial effect of breast cancer on family dynamics, sexuality, and stress management and make appropriate referral to support groups and health care 1,2,3,4 x x x professionals. Manage the adverse effects of antiestrogen medications, such as tamoxifen and 1,2,3,4 x x aromatase inhibitors. Vulvar and vaginal malignancies PGY Pre-invasive lesions PC MK PBL ICS P SBP Level Describe the epidemiology of vulvar intraepithelial neoplasia (VIN) and vaginal 1,2,3,4 x intraepithelial neoplasia (VAIN). Describe the clinical manifestations of VIN and VAIN. 1,2,3,4 x Describe the differential diagnosis of pigmented and nonpigmented vulvar and vaginal 1,2,3,4 x lesions. Perform and interpret the results of diagnostic procedures for VIN and VAIN. 1,2,3,4 x Reviewed July 2014 Perform surgical and/or medical treatment for patients with VIN and VAIN. 1,2,3,4 x Establish a posttreatment follow-up plan for patients with VIN and VAIN. 1,2,3,4 x x Describe the structural and histologic changes in the vagina characteristic of in utero 1,2,3,4 x exposure to diethylstilbestrol. Invasive vulvar carcinoma Describe the epidemiology of invasive vulvar lesions, such as the following: a. Melanoma b. Squamous cell carcinoma c. Basal cell carcinoma 1,2,3,4 x d. Paget disease e. Sarcoma f. Verrucous carcinoma g. Bartholin gland carcinoma Describe the clinical manifestations of invasive vulvar malignancies. 1,2,3,4 x Describe the differential diagnosis of vulvar cancer. 1,2,3,4 x Perform appropriate biopsies to diagnose vulvar carcinoma. 1,2,3,4 x Describe the staging of invasive vulvar cancer using the system adopted by the International Federation of Gynecology and 1,2,3,4 x Obstetrics (FIGO). Counsel a patient about the evaluation and treatment (indications and complications) 1,2,3,4 x x of vulvar cancer. Describe the prognosis for invasive vulvar malignancies.
Load more

Recommended publications
  • Clitoridectomy, Excision, Infibulation- Female Circumcision Ritual and Its Consequences for Women's Health
    Rogala Dorota, Kornowska Joanna, Ziółkowska Mirosława. Clitoridectomy, excision, infibulation- female circumcision ritual and its consequences for women's health. Journal of Education, Health and Sport. 2018;8(11):583-593. eISNN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.2533136 http://ojs.ukw.edu.pl/index.php/johs/article/view/6451 https://pbn.nauka.gov.pl/sedno-webapp/works/896357 The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part B item 1223 (26/01/2017). 1223 Journal of Education, Health and Sport eISSN 2391-8306 7 © The Authors 2018; This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike. (http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 26.11.2018. Revised: 30.11.2018. Accepted: 30.11.2018. Clitoridectomy, excision, infibulation- female circumcision ritual and its consequences for women's health Dorota Rogala ¹, Joanna Kornowska 2, Mirosława Ziółkowska3 1 Department of Oncology, Radiotherapy and Gynecologic Oncology, Faculty of Health Sciences, Collegium Medicum, Nicolaus Copernicus University, Toruń, Poland.
    [Show full text]
  • About Ovarian Cancer Overview and Types
    cancer.org | 1.800.227.2345 About Ovarian Cancer Overview and Types If you have been diagnosed with ovarian cancer or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is Ovarian Cancer? Research and Statistics See the latest estimates for new cases of ovarian cancer and deaths in the US and what research is currently being done. ● Key Statistics for Ovarian Cancer ● What's New in Ovarian Cancer Research? What Is Ovarian Cancer? Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer and can spread. To learn more about how cancers start and spread, see What Is Cancer?1 Ovarian cancers were previously believed to begin only in the ovaries, but recent evidence suggests that many ovarian cancers may actually start in the cells in the far (distal) end of the fallopian tubes. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 What are the ovaries? Ovaries are reproductive glands found only in females (women). The ovaries produce eggs (ova) for reproduction. The eggs travel from the ovaries through the fallopian tubes into the uterus where the fertilized egg settles in and develops into a fetus. The ovaries are also the main source of the female hormones estrogen and progesterone. One ovary is on each side of the uterus. The ovaries are mainly made up of 3 kinds of cells. Each type of cell can develop into a different type of tumor: ● Epithelial tumors start from the cells that cover the outer surface of the ovary.
    [Show full text]
  • Primary Peritoneal Serous Papillary Carcinoma: a Case Series
    Archives of Gynecology and Obstetrics (2019) 300:1023–1028 https://doi.org/10.1007/s00404-019-05280-z GYNECOLOGIC ONCOLOGY Primary peritoneal serous papillary carcinoma: a case series Nikolaos Blontzos1 · Evangelos Vafas1 · George Vorgias1 · Nikolaos Kalinoglou1 · Christos Iavazzo1 Received: 27 May 2018 / Accepted: 22 August 2019 / Published online: 5 September 2019 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Purpose To present the clinical and laboratory characteristics, as well as the management, of patients with primary peritoneal serous papillary carcinoma (PPSPC). Methods This is a retrospective study of 19 patients with PPSPC who underwent debulking surgery followed by frst line chemotherapy and were managed in Metaxa Memorial Cancer Hospital between January 2002 and December 2017. Results The median age of the patients was found to be 66 years (range 44–76 years). Clinical presentation of PPSPC included abdominal distention and pain, constipation, as well as loss of appetite and weight gain. Two of the patients did not mention any symptomatology and the disease was suspected by an abnormal cervical smear and elevated CA125 levels respectively. Biomarkers measurement during the initial management of the patients revealed abnormal values of CA125 for all the participants (median value 565 U/ml). Human epididymis secretory protein 4 (HE4) and ratios of blood count were also measured. Perioperative Peritoneal Cancer Index ranged from 6 to 20. Optimal debulking was achieved in 5 cases. All patients were staged as IIIC and IVA PPSPC and received standard chemotherapy with paclitaxel and carboplatin, whereas bevacizumab was added in the 5 most recent cases. Median overall survival was 29 months.
    [Show full text]
  • Gynecologic Oncology
    Cancer: Gynecologic Oncology FirstHealth Oncology offers a board certified gynecologic oncologist for the evaluation and management of gynecological cancer. As part of the FirstHealth Outpatient Cancer Center a full range of services including education, support services, case management, symptom management and dietary services are available. Gynecologic Oncology Services Available • Management of gynecologic cancers to include ovarian, fallopian tube, Michael Sundborg, M.D. Brian Burgess, D.O. primary peritoneal carcinoma, uterine/endometrial, cervical, vulvar, and vaginal cancers • Advanced surgical management for complex pelvic disease • Administration and management of chemotherapy for gynecological malignancies • Long term surveillance for gynecological malignancies MI • Advanced minimally invasive surgery;DLAND Robotic Surgery RO • Palliative Supportive Care AIRPORT AD RO • Genetic counseling and managementAD for hereditary ovarian, breast and uterine cancers Adara Maness, PA-C • Management for suspected gynecological cancers to include pelvic masses • Management of gynecologic cancer patients via tumor board • Management of pre-invasive disease of the genital tract to include cervix, vulva and vagina MIDLAND RO • Management of gestational trophoblastic diseases to include persistent / invasive molar pregnancies,AD chorio carcinoma, placental site trophoblastic diseases E IEMORE DRIVE AV GE DRIV GE H ROAD SOUT PA PAGE N ROAD NORTH PAGE Main Phone Number: (910) 715-6740 Address: 35 Memorial Drive Entrance 4 Pinehurst, NC 28374 REGIONAL DRIVE LE RC AL DRIVE MEMORI REGIONAL CI E V I R D E G A L IL V T RS FI EPIC: REF 29 1 974-60-21 Cancer: Gynecologic Oncology To refer patients for a consult, call (910) 715-8684. Please give the patient a copy of this form to bring to his/her appointment.
    [Show full text]
  • Creating a New Paradigm in Gynecologic Cancer Care: Policy Proposals for Delivery, Quality and Reimbursement
    Creating a New Paradigm in Gynecologic Cancer Care: Policy Proposals for Delivery, Quality and Reimbursement A Society of Gynecologic Oncology White Paper February 2013 Creating a New Paradigm in Gynecologic Cancer Care February 2013 Table of Contents Executive Summary 3 I. Introduction 6 Purpose of the Report Key Questions II. What is the Society of Gynecologic Oncology? 7 III. Delivering High Quality Gynecologic Cancer Care 9 Weaknesses in Current Delivery Systems Proposed Solutions for Optimizing Delivery Systems Resources Needed to Implement the Care Team Model Ultimate Outcome of the Proposed Care Team Delivery Model IV. Defining High Quality Gynecologic Cancer Care 18 Weaknesses in Current Quality Systems Proposed Solutions and Resources Required to Optimize Quality Measures and Improvement What will be the Ultimate Outcome of this Proposed Quality Improvement System? V. Payment Systems for Delivery of High Quality 24 Gynecologic Cancer Care Weaknesses in Current Payment System Proposed Solutions to Optimize Payment Systems Resources Needed to Facilitate a Demonstration Project Followed by Implementation of New Payment Systems Resources Needed to Facilitate a Demonstration Project Followed by Implementation of New Payment Systems VI. Summary 35 References 37 Appendix 39 Practice Summit Participants 40 Page 2 Creating a New Paradigm in Gynecologic Cancer Care February 2013 Executive Summary The increasing financial burden of cancer care negatively impacts the U.S. health care system, our nation’s economy, and individuals’ quality of life. More importantly, it contributes significantly to premature death. The current health policy environment for cancer care is built upon a system that often rewards volume and intensity of therapy rather than proper coordination and quality of care.
    [Show full text]
  • Capecitabine)
    Reference number(s) 1993-A SPECIALTY GUIDELINE MANAGEMENT XELODA (capecitabine) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. A. FDA-Approved Indications 1. Colorectal Cancer a. Xeloda is indicated as a single agent for adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. b. Xeloda is indicated as first-line treatment in patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. 2. Breast Cancer a. Xeloda in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. b. Xeloda monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated, for example, patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents. B. Compendial Uses 1. Anal cancer 2. Breast cancer 3. Central nervous system (CNS) metastases from breast cancer 4. Colorectal Cancer 5. Esophageal and esophagogastric junction cancer 6. Gastric cancer 7. Head and neck cancer 8. Hepatobiliary cancers (extra-/intra-hepatic cholangiocarcinoma and gallbladder cancer) 9. Occult primary tumors (cancer of unknown primary) 10. Ovarian cancer (Epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer/mucinous cancer) 11.
    [Show full text]
  • Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations
    International Journal of Molecular Sciences Review Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations Isao Otsuka Kameda Medical Center, Department of Obstetrics and Gynecology, Kamogawa 296-8602, Japan; [email protected] Abstract: Ovarian high-grade serous carcinomas (HGSCs) are a heterogeneous group of diseases. They include fallopian-tube-epithelium (FTE)-derived and ovarian-surface-epithelium (OSE)-derived tumors. The risk/protective factors suggest that the etiology of HGSCs is multifactorial. Inflammation caused by ovulation and retrograde bleeding may play a major role. HGSCs are among the most genetically altered cancers, and TP53 mutations are ubiquitous. Key driving events other than TP53 mutations include homologous recombination (HR) deficiency, such as BRCA 1/2 dysfunction, and activation of the CCNE1 pathway. HR deficiency and the CCNE1 amplification appear to be mutually exclusive. Intratumor heterogeneity resulting from genomic instability can be observed at the early stage of tumorigenesis. In this review, I discuss current carcinogenic hypotheses, sites of origin, etiologic factors, and molecular alterations of HGSCs. Keywords: ovarian cancer; high-grade serous carcinoma; carcinogenesis; molecular alterations Citation: Otsuka, I. Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic 1. Introduction Factors, and Molecular Alterations. Ovarian cancer is the most lethal gynecological malignancy. Epithelial ovarian cancers Int. J. Mol. Sci. 2021, 22, 4409. (EOCs) are a heterogeneous group of diseases and can be divided into five main types, https://doi.org/10.3390/ijms based on histopathology and molecular genetics [1]: high-grade serous, low-grade serous, 22094409 endometrioid, clear cell, and mucinous tumors.
    [Show full text]
  • Wellness & Preventive Health
    wellness & preventive health Cancer treatments may increase your chance of developing other health problems years after you have completed treatment. The purpose of this self care plan is to inform you about what steps you can take to maintain good health after cancer treatment. Keep in mind that every person treated for cancer is different and that these recommendations are not intended to be a substitute for the advice of a doctor or other health care professional. Please use these recommendations to talk with your health care provider about an appropriate follow up care plan for you. Surveillance for Your Cancer Breast Cancer Screening Cancer surveillance visit with medical provider that is For more information, see the ACS document Breast focused on detecting signs of recurrence of your cancer. Cancer: Early Detection. For additional information, visit www.livestrong.org or www.cancer.org/cancer/breast-cancer/screening-tests-and- www.cancer.net/patient/Survivorship early-detection.html Frequency depends on type and stage of cancer you had. • Yearly mammograms starting at age 40-49, and (If you had a higher risk cancer, you may be seen more continuing yearly as long as a woman is in good health. often). Your doctor has provided you with a personalized • Clinical breast exam (CBE), performed by a health care cancer treatment summary and survivorship care plan. If professional, every 1-3 years for women aged 25-39, you need another copy, ask your doctor. and every year for women 40 and older. • A monthly breast self-exam (BSE) is a good way to General Cancer Screening for Women monitor breast health.
    [Show full text]
  • Rotation in Gynecologic Oncology
    Department of Obstetrics and Gynecology Externships for Visiting Medical Students Rotation in Gynecologic Oncology Externs choosing this elective rotation will function as student interns in the Division of Gynecologic Oncology. The Gynecologic Oncology Team cares for a diverse, multiethnic population of both county and private patients. The inpatient care takes place entirely on campus at Parkland Memorial Hospital and the William P. Clements Jr. University Hospital. The Gyn Onc Team consists of five faculty members, four gynecologic oncology fellows (two clinical and two laboratory fellows), and six Parkland residents. Externs will be integrated into this team to provide care for all women diagnosed with gynecologic malignancies at our institutions. During your time here, you will have both inpatient and outpatient experiences at Parkland Hospital as well as Clements University Hospital and the Harold C. Simmons Comprehensive Cancer Center. As an extern, you will scrub and assist in surgical cases and follow patients postoperatively. You will have a role in in-house consultations as well as medical admissions and will also have the opportunity to share your knowledge during daily ward rounds. Other tasks will include performing H&Ps on new clinic patients as well as seeing follow-up patients and learning chemotherapy options and side effects. You will also attend the resident didactic conferences and the gyn onc conferences. Our busy clinical service provides comprehensive clinical and surgical exposure for visiting students and offers the opportunity to learn about the diagnosis and treatment of gynecological cancers. This rotation is intended to provide an intense clinical experience with an emphasis on teaching.
    [Show full text]
  • XELODA (Capecitabine)
    Reference number(s) 1993-A SPECIALTY GUIDELINE MANAGEMENT XELODA (capecitabine) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. A. FDA-Approved Indications 1. Colorectal Cancer a. Xeloda is indicated as a single agent for adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. b. Xeloda is indicated as first-line treatment in patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. 2. Breast Cancer a. Xeloda in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. b. Xeloda monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated, for example, patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents. B. Compendial Uses 1. Anal cancer 2. Breast cancer 3. Central nervous system (CNS) metastases from breast cancer 4. Colorectal Cancer 5. Esophageal and esophagogastric junction cancer 6. Gastric cancer 7. Head and neck cancers (including very advanced head and neck cancer) 8. Hepatobiliary cancers (including extrahepatic and intra-hepatic cholangiocarcinoma and gallbladder cancer) 9. Occult primary tumors (cancer of unknown primary) 10. Ovarian cancer, fallopian tube cancer, and primary peritoneal cancer: Epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and mucinous cancer) 11.
    [Show full text]
  • Ovarian Cancer: the New Paradigm (And What You Need to Know Clinically)
    Ovarian Cancer: The New Paradigm (and what you need to know clinically) Dianne Miller, M.D., FRCSC University of British Columbia and the British Columbia Cancer Agency Ovarian Cancer y Germ Cell: y Stromal tumors y Dysgerminoma y Lymphoma y Endodermal sinus y Sarcoma etc. y Teratoma etc. y Epithelial Tumors y Sex cord stromal y Serous y Granulosa cell y Mucinous y FOX L2 y Endometriod y Sertoli leydig etc y Clear cell etc. Objectives y To discuss why epithelial ovarian cancer is becoming vanishingly rare! y To discuss our new insights into ovarian cancer y Epithelial Ovarian Cancer is a least five distinct diseases y High Grade Serous* y Endometriod* y Clear cell* y Mucinous y Low Grade Serous y (and possibly transitional cell) y To discuss the clinical implications of the changes in our understanding of the origin of “Ovarian Cancers” “Ovarian” Cancer in Canada y modest lifetime risk of 1/70, but: y major public health issue: y 2500 new cases/annum: 1750 deaths y potential years of life lost from cancer: y breast 94,400 = 1.0 y ovary 28,600 0.3 y uterus 11,400 y cervix 10,100 International Benchmarking y The Lancet, Volume 377, Issue 9760, Pages 127 ‐ 138, 8 January 2011 y Published Online: 22 December 2010 y Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995—2007 (the International Cancer Benchmarking Partnership): an analysis of population‐based cancer registry data “Ovarian Cancer” y Screening ineffective y Survival rates low & stable “Ovarian Cancer” Presentation y 1/3 gradual intrapelvic growth → y lower
    [Show full text]
  • 1 the Influence of Chemotherapy-Induced Peripheral
    The Influence of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life of Gynecologic Cancer Survivors ABSTRACT Objective: The aim of this observational study was to investigate correlations between long-term chemotherapy-induced peripheral neurotoxicity (CIPN) and quality of life (QOL) (physical well-being, social well-being, emotional well-being [EWB], and functional well-being [FWB]) among survivors of gynecologic cancer (GC). Methods: We aimed to assess the correlation of QOL and long-term CIPN with the temporal change in recurrence-free GC survival. Questionnaire responses and clinical data of 259 GC survivors were collected and assessed according to treatment received. The χ2 test was used to determine the significance of correlations. Results: Of 165 evaluable patients treated by chemotherapy, 36 patients (21.8%) developed CIPN of Common Toxicity Criteria for Adverse Events Grade ≥1 during the study. CIPN had significantly improved over time in the domain of FWB at ≥61 months after the end of chemotherapy (post-treatment4) among GC survivors (p=0.003). Furthermore, CIPN treated by more than 6 courses of the paclitaxel and carboplatin 1 (TC) regimen among GC survivors showed significant improvement over time in the EWB domain at 25–60 months and ≥61 months after the end of chemotherapy (post-treatment3 and 4) (p=0.037 and p=0.023) and in FWB at post-treatment4 (p<0.001). Conclusions: Emotional and functional domains of CIPN improved over time among GC survivors treated by more than 6 courses of the TC regimen. Based on these results, further research is required to identify additional preventative or curative approaches.
    [Show full text]